| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Other Events
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs |
| 08 Oct 2026 |
8-K: Other Events
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors |
| 01 Oct 2026 |
8-K: Other Events
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology |
| 14 Sep 2026 |
8-K: Other Events
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors |
| 08 Sep 2026 |
8-K: Other Events
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology |
| 10 Aug 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 03 Aug 2026 | 8-K: Other Events |
| 01 Jul 2026 | 8-K: Other Events |
| 01 Jun 2026 | 8-K: Other Events |
| 27 May 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 22 May 2026 | 8-K: Other Events |
| 11 May 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 04 May 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 20 Apr 2026 | 8-K: Other Events |
| 01 Apr 2026 | 8-K: Other Events |
| 16 Mar 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 03 Feb 2026 | 8-K: Entry into a Material Definitive Agreement; Other Events |
| 02 Feb 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 14 Jan 2026 | 8-K: Other Events |
| 12 Jan 2026 | 8-K: Other Events |
Loading...
